Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 2: Long-term safety and tolerability of pediatric bosentan in idiopathic or familial pulmonary arterial hypertension
2005-001967-70Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bosentan in Plexogenic Pulmonary Arteriopathy and pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Long-term safety of pediatric bosentan, Long-term tolerability of pediatric bosentan and 2 more. Started Aug 2005; status: completed.
02
Drugs
bosentan
03
Conditions
Plexogenic Pulmonary Arteriopathypulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2005-001967-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001967-70.